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The term "pharmacogenetics" refers to the study of individual genetic variations that give rise to different re-
sponses to the intake of a drug. Recently, however, it has begun to think that an important role in this sense can 
also be played by our microbiota. The interaction between our gut microbial flora and drugs is actually bidirec-
tional: evidence has accumulated that some drugs, in addition to classical antibiotics, have a strong impact on the 
composition of the microbiota.  
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1. Introduction 
 
The term microbiota refers to the millions of 
billions of microorganisms (bacteria of thou-
sands of different species, Archaea, viruses, and 
fungi that crowd our organism). These mi-
crobes live on the skin, in the mucous mem-
branes of the mouth, in the respiratory tract, 
but a particularly important role is played by the 
intestinal component, a diverse and dense mi-
crobial community, unparalleled in other bodily 
habitats. At birth, the digestive tract is almost 
sterile: the intestinal microbiota is transferred 
from the mother to the child during childbirth, 
when it occurs naturally, and this process of 
colonization continues during the first days of 
life, with different species depending on wheth-
er the infant is artificially or breastfed. It then 
undergoes a prolonged period of postnatal de-
velopment, during which it is influenced by 
contact with external agents such as foods, 
metals, and toxic substances. 
It is estimated that the intestinal bacterial herit-
age of an adult is composed of over one hun-
dred trillion cells, most of which belong to six 
bacterial phyla: Firmicutes, Bacteroidetes, Actinobac-
teria, Proteobacteria, Fusobacteria and Verrucomicro-
bia. They perform functions essential to our 
health, such as the breakdown of plant polysac-
charides - fibers - indigestible by the host, the 
detoxification of xenobiotics, substances for-
eign to the body, the suppression of the growth 
of harmful microorganisms by competitive ex-
clusion and the development of the host im-
mune system, the biosynthesis of essential vit-
amins and amino acids. For example, our or-
ganism is unable to produce vitamin K, which 
is essential for the proper synthesis of coagula-
tion factors, and uses, in addition to the diet, 
that which is produced by some bacteria of our 
resident intestinal microbial flora. 
The healthy pulmonary microbiota contains 
many commensal bacteria derived from the up-
per respiratory tract, mainly belonging to the 
phylum Bacteroidetes, especially the genus Prevotel-
la, and the phylum Firmicutes, especially Veilonel-
la and Streptococcus (Dickson et al. 2015). Its 
composition is determined by numerous factors 
and anatomo-clinical circumstances: a) dis-
placement of bacteria from the upper airways 
by passive migration, b) gastroesophageal mi-
cro-aspiration from the digestive tract c) sapro-
phytic anti-infective activity by the innate and 
adaptive defenses of the healthy lung, d) by 
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productive catarrhal cough and altered mucocil-
iary clearance that modulate pathological cellu-
lar and bacterial migration (Dickson and Huff-
nagle 2015).  
The healthy lung microbiota acts as a guardian 
of respiratory health by providing local immu-
nologic defense factors that prevent coloniza-
tion of opportunistic pathogens by triggering 
eosinophilic and/or neutrophilic cellular in-
flammatory processes (Dekaboruah et al. 2020). 
The dramatic disruption of this respiratory 
commensal flora (termed pulmonary dysbiosis) 
in patients with chronic lung disease alters the 
physiological taxonomic composition resulting 
in acute inflammation that has been associated 
with the chronic inflammatory pathogenesis of 
lung disease.  
The balance between our organism and the bac-
terial flora that inhabits it is therefore valuable, 
but the composition of the microbiota is highly 
dynamic and shows substantial inter-individual 
and intra-individual variations. It is closely re-
lated to the age and genetics of the host, but al-
so to environmental factors such as season, 
smoking, number of hours of sleep, even con-
sumption of carbonated beverages and type of 
diet (Falony et al. 2016). 
 
2. How drugs interact with intestinal microbiota 
 
Evidence has accumulated that some drugs, in 
addition to classical antibiotics, have a strong 
impact on the composition of the microbiota. 
With few exceptions, drugs do not see their site 
of action in the intestine but, if they are admin-
istered orally, they reach it to be absorbed there 
and then distributed, thanks to blood-mediated 
transport, throughout the body. Naturally, it is 
difficult to determine precisely how much drug 
will reach the site of action and how long it re-
mains there. Also, for this reason it is difficult 
to determine what effect it may have on the res-
ident intestinal flora and vice versa. 
While it is easy for antibiotics to understand 
how they can alter the composition of the intes-
tinal flora depending on their spectrum of ac-
tion, it was more surprising to see evidence of a 
bactericidal effect on many non-antibiotic 
drugs. A study published in 2018 analyzed 
about a thousand non-antibiotic drugs and 
showed that 24% of them, including mostly 
agents used in the treatment of mental disor-
ders, antidiabetics, and anticancer agents and 
inhibited, in vitro, the growth of representative 
strains of bacterial flora (Maier et al. 2018). 
Alterations in the composition of the intestinal 
flora are linked to mental disorders such as anx-
iety, schizophrenia, bipolar disorder and de-
pression. Drugs used to treat these illnesses 
have been found to interact significantly with 
the microbiota. The first marketed antidepres-
sant, iproniazide, a monoamine oxidase inhibi-
tor, is now used as a drug to treat tuberculosis 
due to its ability to kill the mycobacterium re-
sponsible. 
Some widely used antidepressants, such as se-
lective serotonin reuptake inhibitors (SSRIs), 
have been shown to inhibit the efflux pumps of 
bacteria and thus prevent their replication. 
Phenothiazines (and some derivative molecules 
used as antihistamines), the largest class of anti-
psychotics, have also been associated with anti-
infective properties. In this regard, that of anti-
psychotic drugs is a particularly interesting 
chapter: numerous studies have been conducted 
on their interaction with the bacterial flora, and 
it has been shown that the administration of 
atypical antipsychotics as recently introduced 
psychotropic drugs that are more tolerated than 
their predecessors, induces dysbiotic alterations 
to the composition of the intestinal microbiota. 
Interestingly, there is an inverse relationship, as 
antibiotic-induced dysbiosis has been linked to 
mental disorders such as anxiety and depression 
(Mognetti 2020). 
It has been proposed that many of the metabol-
ic side effects associated with the use of atypical 
antipsychotics, including weight gain, cardi-
ometabolic disorders, and development of the 
metabolic syndrome, are the result of pharma-
cological action on the microbiota. For exam-
ple, long-term exposure to risperidone increases 
the Firmicutes/Bacteroidetes ratio, which is associ-
ated with obesity. In addition, a decrease in 
Akkermansia muciniphila has been observed in 
patients treated with atypical antipsychotics, 
and this species is known to have beneficial an-
ti-inflammatory effects and to adversely affect 
fat mass development. An experimental study 
in mice lacking bacterial flora (germ-free) then 
revealed that the gut microbiota was responsi-
ble for the weight gain observed in response to 
olanzapine treatment. Similarly, the side effects 
of these drugs on metabolism were partially re-
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versed in female rats when administered con-
comitantly with an antibiotic (Flowers et al. 
2017). Taken together, these results demon-
strate that atypical antipsychotics can have a 
profound impact on host metabolism through 
their effects on the gut microbiota. 
Sometimes the effect of the drug on the com-
position of the intestinal flora is indirect. Pro-
ton pump inhibitors (gastroprotective drugs 
widely used, for example in the treatment of 
gastric ulcer or gastroesophageal reflux diseas-
es) modify the pH of the gastrointestinal tract, 
thus favoring the proliferation of bacterial spe-
cies that prefer a more basic environment to 
the detriment of those that prefer an acid envi-
ronment. Proton pump inhibitor users have 
been shown to have a larger bacterial flora con-
sisting of more species than non-users (Imhann 
et al. 2016; Jackson et al. 2016). 
The list of non-antibiotic drugs capable of 
modifying the composition of the intestinal mi-
crobiota is long, and includes, among others, 
hormonal contraceptives, laxatives and antihis-
tamines. However, in many cases we do not 
know how this happens and if the impact is rel-
evant for the whole flora or only for some bac-
terial species, also considering other parameters 
such as contact times and the amount of drug 
that actually remains in the intestine (Mognetti 
2020). 
 
3. Microbiota action on active drugs 
 
Some drugs can modify the composition of the 
bacterial flora, but numerous studies have 
shown that contextually, it is capable of modify-
ing many of the active ingredients of the drugs 
with which it comes into contact, similar to 
what it is able to do on molecules that we nor-
mally introduce with food (Kåhrström, Pari-
ente, and Weiss 2016). Several drugs that can be 
modified by the gut microbiota have already 
been identified, including omeprazole, a gastro-
protectant, clonazepam, an anxiolytic, the anti-
diarrheal loperamide, and many others. The list 
of drugs subject to modification by the intesti-
nal flora is certainly incomplete, since systemat-
ic analyses on microbial metabolism are still 
lacking, also in light of the great inter- and in-
tra-individual variability of the bacterial flora. 
A documented example in which the action of a 
bacterium component of our intestinal micro-
biota negatively affects the effect of a drug is 
Eggerthella lenta, a bacterium known to possess 
an enzyme by which it inactivates digoxin, a 
valuable drug of plant origin used to treat heart 
failure. 
Similarly, other rations that certain bacterial 
species perform on specific drugs have been 
identified. Except in rare cases, however, we do 
not know whether these reactions modify the 
effect of the drug and in what way. It is possi-
ble that bacterial-induced changes in vivo en-
hance the effect of the drug, in which case they 
would be beneficial to the user. Or they could 
be responsible for certain collateral effects, a 
hypothesis that has been put forward especially 
for drugs that have repercussions at the gastro-
intestinal level or that, as in the case of some 
antipsychotics, cause an increase in body 
weight. In this sense, is paradigmatic the case of 
irinotecan, an anticancer drug that our body 
binds to a molecule called glucuronic acid in 
order to eliminate it more easily. The complex 
irinotecan-glucuronic acid, in addition to being 
less toxic than the original drug, is also more 
easily removed with the feces. Some bacteria in 
our intestinal flora are equipped with an en-
zyme, beta-glucuronidase, which can break 
down the bond between the drug and the co-
factor, thus returning the drug to its original 
form and toxicity. 
Therefore, given the ability of our commensal 
bacteria to modify the drugs that transit in our 
intestine, it was thought to intervene on these 
reactions, to limit them when they are harmful 
or to exploit them when they are favorable to 
the host. For example, with reference to the 
case of irinotecan, researchers have found a way 
to prevent the activity of beta-glucuronidase 
with inhibitors that do not modify the composi-
tion of the bacterial flora nor give an effect on 
our organism. This would allow the anticancer 
drug to be administered while limiting its toxici-
ty. Other interventions have been devised in 
this sense: for example, it has been demonstrat-
ed that modifying through probiotics or antibi-
otics the composition of the bacterial flora by 
including some species of gram-positive bacte-
ria, influences the effectiveness of the antineo-
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Many studies are focusing on the potential of 
microbiota-based medicine. Continued advanc-
es in the field could lead to targeted approaches 
to improve drug outcomes by modifying the 
gut bacterial makeup and to have drug out-
comes predicted based on the composition of 
everyone’s flora. However, it will not be easy to 
incorporate the role of our bacterial flora into 
toxicology and pharmacology: drug-microbiota-
host interactions are inherently complicated and 
as such require a complex combination of ex-
perimental and computational approaches to 
dissect them. In any case, developing tools, in-
cluding dietary, or even synthetically engineered 
probiotics and bacteria through which to ma-
nipulate the microbiota for therapeutic purpos-
es would allow us to better respond to a drug or 
limit its side effects. 
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